Bexarotene might be effective in patients with high risk scores, and its anti-HNSCC efficacy was evidenced by targeting the PPARγ/RXRα heterodimer oral cancer preclinical test (Rosas et al., 2022). This evidence concerns the gene RXRA and lip and oral cavity carcinoma.